Medicare’s approach to reimbursing new drugs for dialysis patients in the end-stage renal disease bundled payment system may be applied to two new first-in-class drugs in 2022, and stakeholders will be watching to see how uptake among dialysis providers responds.
The Centers for Medicare and Medicaid Services provides transitional drug add-on payment adjustments (TDAPA) to innovative new drugs to help...